Cited by 379Hepatitis C virus researchDrug-Induced Hepatotoxicity and ProtectionLiver physiology and pathology

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients: Mitoquinone and liver damage

Gane, Edward J., Weilert, Frank, Orr, David W., Keogh, Geraldine F., Gibson, Michael, Lockhart, Michelle M., Frampton, Christopher M., Taylor, Kenneth M., Smith, Robin A. J., Murphy, Michael P.·2010·Liver International

DOI 10.1111/j.1478-3231.2010.02250.x

Open this paper in CoChat — free account

Abstract

BACKGROUND: Increased oxidative stress and subsequent mitochondrial damage are important pathways for liver damage in chronic hepatitis C virus (HCV) infection; consequently, therapies that decrease mitochondrial oxidative damage may improve outcome. The mitochondria-targeted anti-oxidant mitoquinone combines a potent anti-oxidant with a lipophilic cation that causes it to accumulate several-hundred fold within mitochondria in vivo. AIMS: In this phase II study, we investigated the effect of oral mitoquinone on serum aminotransferases and HCV RNA levels in HCV-infected patients. METHODS: Thirty HCV patients who were either non-responders or unsuitable candidates for standard-of-care (pegylated interferon plus ribavirin) were randomized to receive mitoquinone (40 or 80 mg) or placebo once daily for 28 days, and serum aminotransferases and HCV RNA levels were measured. RESULTS: Both treatment groups showed significant decreases in absolute and percentage changes in serum alanine transaminase (ALT) from baseline to treatment day 28 (P<0.05). There was also a significant difference between incremental area under the curve for ALT between baseline and day 28 for the 40 mg treatment group against placebo (P<0.05). The differences in plasma ALT activity from baseline to day 28 in both mitoquinone groups compared with placebo did not reach significance (P>0.05). There was no change in HCV load on mitoquinone treatment. CONCLUSIONS: Administration of the mitochondria-targeted anti-oxidant mitoquinone significantly decreased plasma ALT and aspartate aminotransferase in patients with chronic HCV infection, and this suggests that mitoquinone may decrease necroinflammation in the liver in these patients. As mitochondrial oxidative damage contributes to many other chronic liver diseases, such as steatohepatitis, further studies using mitochondria-targeted anti-oxidants in HCV and other liver diseases are warranted.

Integrity signals

Registry

Crossref · 10.1111/j.1478-3231.2010.02250.x

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
Self-citation
Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,457
The global burden of hepatitis C
Lavanchy, D. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01934.x · Cited by 1,353
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J. W. F., Heathcote, E. J., Lai, M., Gane, E. J., O’Grady, J., Reichen, J., Moisés Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,218
Self-citation
Targeting Antioxidants to Mitochondria by Conjugation to Lipophilic Cations
Murphy, M. P., & Smith, R. A. J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105110 · Cited by 1,173
Self-citation
Selective Targeting of a Redox-active Ubiquinone to Mitochondria within Cells
Kelso, G. F., Porteous, C. M., Coulter, C. V., Hughes, G., Porteous, W. K., Ledgerwood, E. C., Smith, R. A. J., & Murphy, M. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009093200 · Cited by 1,091
Self-citation
Global surveillance and control of hepatitis C
(1999) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.1999.6120139.x · Cited by 903
Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C
Liang, T. J., Rehermann, B., Seeff, L. B., & Hoofnagle, J. H. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-4-200002150-00008 · Cited by 867
Non‐alcoholic fatty liver disease
Angulo, P., & Lindor, K. D. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.17.s1.10.x · Cited by 838
Delivery of bioactive molecules to mitochondria in vivo
Smith, R. A. J., Porteous, C. M., Gane, A. M., & Murphy, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931245100 · Cited by 725
Self-citation

Show all 33 references

Research works printed but not linked: 5

Reddy, 2009, Ribavirin, current role in the optimal clinical management of chronic hepatitis C, 50, 402
Chandran, 2009, Doxorubicin inactivates myocardial cytochrome c oxidase in rats, cardioprotection by Mito-Q, 96, 1388
Murphy, 2000, Drug delivery to mitochondria, the key to mitochondrial medicine, 41, 235
Snow, 2008, Phase II study of the mitochondrial antioxidant mitoquinone for Parkinson's disease, Neurology, 70, A483
Begriche, 2006, Mitochondrial dysfunction in NASH, causes, consequences and possible means to prevent it, 6, 1

Sorted by citations

Items 301–379 of 379

Mitochondrial ROS inhibition prevents doxorubicin-induced breast cancer cell migration and invasion
Capelôa, T., de Velde, J. A. V., Pranzini, E., Ippolito, L., Zampieri, L. X., Tardy, M., Vazeille, T., Provito, A., Carrà, G., Scalera, A., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113031 · Cited by 6
Utilization of mitochondrial-targeted small molecules in protecting stored platelets against storage lesions
Zhang, Y., Wang, J., Lei, S., Hu, Y., & Fu, L. (2022) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2022.100070 · Cited by 5
Flow Synthesis of Nature-Inspired Mitochondria-Targeted Phenolic Derivatives as Potential Neuroprotective Agents
Pecora, D., Annunziata, F., Pegurri, S., Picone, P., Pinto, A., Nuzzo, D., & Tamborini, L. (2022) · Antioxidants · doi:10.3390/antiox11112160 · Cited by 5
Unbiased complexome profiling and global proteomics analysis reveals mitochondrial impairment and potential changes at the intercalated disk in presymptomatic R14Δ/+ mice hearts
Foo, B., Amedei, H., Kaur, S., Jaawan, S., Boshnakovska, A., Gall, T., de Boer, R. A., Silljé, H. H. W., Urlaub, H., Rehling, P., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311203 · Cited by 8
Immunopathogenesis of Autoimmune Liver Damage
Czaja, A. J. (2017) · Technical report · doi:10.1016/b978-0-444-63707-9.00002-7 · Cited by 5
Mitoquinol mesylate alleviates oxidative damage in cirrhotic and advanced hepatocellular carcinogenic rats through mitochondrial protection and antioxidative effects
Sulaimon, L. A., Adisa, R. A., Samuel, T. A., Abdulkareem, F. B., & Ayankojo, A. G. (2021) · Advances in Redox Research · doi:10.1016/j.arres.2021.100014 · Cited by 5
Altered mitochondrial function: a clue therapeutic strategies between metabolic dysfunction-associated steatotic liver disease and chronic kidney disease?
Bai, J., Zhang, L., He, L., & Zhou, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1613640 · Cited by 6
A bench to bedside perspective on anthracycline chemotherapy-mediated cardiovascular dysfunction: challenges and opportunities. A symposium review
Clayton, Z. S., Ade, C. J., Dieli-Conwright, C. M., & Mathelier, H. M. (2022) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00471.2022 · Cited by 3
Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans: an exploratory single center pragmatic open label non-randomized pilot clinical trial with matched controls
Chen, K., JACKSON, N. J., & Kelesidis, T. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105042 · Cited by 4
Exploiting endobiotic metabolic pathways to target xenobiotic antioxidants to mitochondria
Anders, M. W. (2012) · Mitochondrion · doi:10.1016/j.mito.2012.10.015 · Cited by 4
Cardioprotective Effects of Mitochondrial-Targeted Antioxidants in Myocardial Ischemia/Reperfusion (I/R) Injury
Ondrasik, R. M., Chen, Q., Navitsky, K., Chau, W. L., Devine, I., Lau, O., Galbreath, T., Barsotti, R., & Young, L. H. (2013) · American Peptide Symposium (APS) · doi:10.17952/23aps.2013.064 · Cited by 4
Mitochondrial Targeting of Antioxidants
Zinovkin, R. A., Bakeeva, L. E., Chernyak, B. V., Egorov, M. V., Исаев, Н. К., Kolosova, N. G., Korshunova, G. A., Манских, В. Н., Moshkin, M. P., Plotnikov, E. Y., et al. (2014) · Springer eBooks · doi:10.1007/978-3-642-30018-9_9 · Cited by 3
Oxphos targeting of MYCN-amplified neuroblastoma
Epp, S., Egan, D., Poon, E., Aziz, A. A. A., Wynne, K. J., Chesler, L., Halász, M., & Kölch, W. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1613751 · Cited by 5
Mitochondrial Free Radicals, Antioxidants, Nutrient Substances, and Chronic Hepatitis C
Guo, C.-H., & Che, P.-C. (2012) · InTech eBooks · doi:10.5772/51315 · Cited by 4
Reactive Oxygen Species (ROS) and Liver Disease Therapy
Bellanti, F., Sastre, J., & Serviddio, G. (2014) · Springer eBooks · doi:10.1007/978-3-642-30018-9_141 · Cited by 4
Reactive Oxygen Species-Mediated Mitochondrial-Targeted Therapeutics in Hepatic Disorders: Current Progress and Future Opportunities
Dhiman, A., Shah, Y., Chaudhary, U., & Garkhal, K. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00145 · Cited by 4
Oxidative Stress in Glaucoma: From Pathogenic Mechanisms to Emerging Antioxidant Therapies
Hanyuda, A., Tsuda, S., Takahashi, N., Sato, M., Sato, K., Himori, N., & Nakazawa, T. (2026) · Antioxidants · doi:10.3390/antiox15060751 · Cited by 3
Platelet Bioenergetics and Associations With Delirium and Coma in Patients With Sepsis
Onyemekwu, C. A., Prendergast, N. T., Potter, K. M., Toney, N. A., Nouraie, M. S., Shiva, S., & Girard, T. D. (2024) · CHEST Critical Care · doi:10.1016/j.chstcc.2024.100076 · Cited by 3
Treatment of Mitochondrial Disturbances due to Early Life Adversity in Mice Results in Restoration of Complex I Activity and Normal Reward Behavior
Eagleson, K. L., & Levitt, P. R. (2025) · eNeuro · doi:10.1523/eneuro.0172-25.2025 · Cited by 4
Multifunctional Radical Quenchers as Potential Therapeutic Agents for the Treatment of Mitochondrial Dysfunction
Ji, X., Khdour, O. M., & Hecht, S. M. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0481 · Cited by 3
Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone
Bennett, M. G. A., Meakin, A. S., Botting, K. J., Niu, Y., Ford, S. G., Murphy, M. P., Wiese, M. D., Giussani, D. A., & Morrison, J. L. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030285 · Cited by 3
Self-citation
The role of mitochondria-targeted antioxidant MitoQ in neurodegenerative disease
Zhang, L., Reyes, A., & Wang, X. (2018) · Journal of Green Engineering · doi:10.13052/2052-8426-2018-01 · Cited by 3
Long-Term Functional and Structural Renoprotection After Experimental Acute Kidney Injury in Subclinical Chronic Kidney Disease In Vivo
Herath, S., Au, A. Y. M., Taylor, K. M., Kapoor‐Kaushik, N., Endre, Z. H., & Erlich, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104616 · Cited by 2
Self-citation
Mitochondria at the heart of aging: structure, function, and failure
Marei, H. E. S. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08047-8 · Cited by 7
ALSUntangled No. 29: MitoQ
The ALSUntangled Group (2015) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2015.1050897 · Cited by 2
Impaired Redox Homeostasis and Cardiovascular Aging
Simsek, B., & Afzal, J. M. (2021) · Healthy ageing and longevity · doi:10.1007/978-3-030-84965-8_4 · Cited by 2
MitoQ Supplementation During Vigorous Training Improves Reactive Oxygen Species, Glutathione Peroxidase, and miRNAs Regulating Vascular Inflammation in Cyclists
Aminizadeh, S., Lee, J., Zarezadehmehrizi, A., Najafipour, H., Ahmadi, M. A., Moflehi, D., Rashidzadeh, H., & Park, Y. (2023) · Brazilian Archives of Biology and Technology · doi:10.1590/1678-4324-2023220914 · Cited by 2
MitoQ for vitiligo by mitigating PARP1 translocation aberrations: Network pharmacology and experimental validation
Xiong, R., Jin, S., Li, Y., Dong, T., Song, X., & Guan, C. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2025.119995 · Cited by 2
Surface Modification of Nanocarriers for Specific Cell Targeting for Better Therapeutic Effect
Milani, D., Athiyah, U., Hariyadi, D. M., & Pathak, Y. V. (2019) · Springer eBooks · doi:10.1007/978-3-030-06115-9_18 · Cited by 2
Regulation of Synovial γδ T Cell Ligand Expression by Mitochondrial Reactive Oxygen Species and Gasdermin-D
Collins, C. C., Hahn, P., Jiang, Z., Fitzgerald, K. A., Xiao, T. S., & Budd, R. C. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2101166 · Cited by 2
Antioxidant MitoQ increases viability of human corneal endothelial cells with congenital hereditary endothelial dystrophy-associated SLC4A11 mutations
Peshkar-Kulkarni, S., Chung, D. D., & Aldave, A. J. (2025) · Ophthalmic Genetics · doi:10.1080/13816810.2025.2450455 · Cited by 1
Kai-Xin-San alleviates Alzheimer's disease by targeting the DHFR-mediated folate-mitochondrial axis
Shao, S., Zu, R., Lu, H., Yuan, Y., Chen, Y., Wu, C., Yang, Y., Shao, S., Ma, H., Zhang, Z., et al. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121230 · Cited by 1
Targeting Mitochondria in Aging‐Related Diseases: Therapeutic Potential and Obstacles
Xiang, Z., Chen, Y., Liu, X., Lu, H., Yang, Y., Xing, L., Zhang, Y., Lang, C., Zhang, S., Zhao, S., et al. (2026) · MedComm · doi:10.1002/mco2.70790 · Cited by 2
Eight weeks of MitoQ supplementation does not alter kidney function or urinary kidney injury biomarkers in middle-aged and older adults
Stute, N. L., Muma, J. P., Hutchison, Z. J., Culver, M. N., Linder, B. A., Sanchez, S. O., Kirkman, D. L., Gutiérrez, O. M., Kavazis, A. N., & Robinson, A. T. (2026) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00174.2026 · Cited by 1
Mitochondrial antioxidant therapy fails to improve obese asthma outcomes
Dixon, A. E., Garrow, O. J., CALLAS, P. W., Morris, C. R., Bates, J. H. T., Martin, F. K., Barbieri, S., Higdon, M., Anathy, V., & Que, L. G. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.109122 · Cited by 1
Mitochondria-targeted antioxidants: coenzyme Q10, mito-Q and beyond
López‐Lluch, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90256-4.00013-8 · Cited by 1
Mitochondrial Disruption in Viral‐Mediated Neuronal Injury: A Mechanistic Perspective
Shi, S., Zhai, M., Wu, B., & Sun, W. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70626 · Cited by 1
Antioxidant Approach to the Therapy of Chronic Liver Diseases
Thủy, L. T. T., Hai, H., & Kawada, N. (2015) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-319-15539-5_18 · Cited by 1
Therapeutic targeting of cardiolipin composition in injury and disease using TPP-conjugated compounds
Bagshaw, O. R. M., Atkinson, J., Fajardo, V. A., LeBlanc, P. J., & Stuart, J. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819621-2.00020-6 · Cited by 1
Therapeutic targeting of the mitochondrial reactive oxygen species engine prevents portal hypertension and hepatic fibrogenesis
Weiskirchen, R. (2017) · Liver International · doi:10.1111/liv.13442 · Cited by 1
Interplay between mitochondria and reactive oxygen and nitrogen species in metabolic adaptation to hypoxia in facioscapulohumeral muscular dystrophy: potential therapeutic targetsPreprint
Heher, P., Ganassi, M., Weidinger, A., Engquist, E., Prüller, J., Nguyen, T., Tassin, A., Declèves, A., Mamchaoui, K., Grillari, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.08.459509 · Cited by 1
The Contribution of DNA Interstrand Crosslinks to Aging
Robinson, A. R. (2012) · D-Scholarship@Pitt (University of Pittsburgh)
Role of Integrative Medicine in Liver Transplantation
Bazzan, A. J., Newberg, A. B., & Monti, D. (2016) · Springer eBooks · doi:10.1007/978-3-319-05543-5_31-2
Mitocodria: de la célula al clínica, caso de la sepsis
Díaz, E. S., González, D. G., Cárdenas, J. S. M., & Vèlez, C. A. A. (2014) · Archivos de Medicina (Manizales) · doi:10.30554/archmed.14.2.268.2014
Synthesis and Characterization of 4-Thiobutyl-triphenylphosphonium-pantetheine, a Pantetheine Derivative
Lambrechts, R. A. (2014) · Chemical Science International Journal · doi:10.9734/acsj/2014/7335
REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014)
Unifying Mechanism of Antiviral Drug Action Based on Electron Transfer and Reactive Oxygen Species
Kovacic, P., & Somanathan, R. (2015) · ACS symposium series · doi:10.1021/bk-2015-1200.ch007
Reply: Glial mitochondropathy in infantile neuroaxonal dystrophy: pathophysiological and therapeutic implications
Kinghorn, K. J., Castillo-Quan, J. I., Li, L., Bhatia, K. P., Abramov, A. Y., Hardy, J., & Partridge, L. (2016) · Brain · doi:10.1093/brain/aww185
Mitochondrial oxidative stress and antioxidant therapy in arterial aging
Gioscia‐Ryan, R. A. (2016) · CU Scholar (University of Colorado Boulder)
The Role Of Thiocyanate In Modulating Tissue Damage In Cardiovascular Disease
Hall, L. (2017) · The Sydney eScholarship Repository (The University of Sydney)
The Near Future of HCV Treatment: Supplementary Treatments against Oxidative Stress will be still useful?
Arciello, M. (2014) · Journal of Biomolecular Research & Therapeutics · doi:10.4172/2167-7956.1000e131
Emerging Therapies: What’s on the Horizon?
Redahan, L., & Murray, P. T. (2018) · Springer eBooks · doi:10.1007/978-1-4939-8628-6_21
Drug Delivery Systems: Mitochondria-Targeted
Yamada, Y., & Harashima, H. (2015) · Taylor & Francis eBooks · doi:10.1081/e-ebpp-120050056
Oxidative stress in viral HEPATITIS B and C
Namıduru, E. S., & Namıduru, M. (2019) · Asian Pacific Journal of Health Sciences · doi:10.21276/apjhs.2019.6.4.10
Novel approaches to treat mitochondrial complex-I mediated defects in disease
Perry, J. B. (2019) · VTechWorks (Virginia Tech)
Modulation of the inflammatory response in hibernation and calorie restriction
Reitsema, V. A. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.194860187
In brief
(2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.130
Mitochondrial failure in sepsis
van der Slikke, K. (2022) · doi:10.33612/diss.222666046
Role of Integrative Medicine in Liver Transplantation
Bazzan, A. J., Newberg, A. B., & Monti, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-07209-8_31
Role of Integrative Medicine in Liver Transplantation
Bazzan, A. J., Newberg, A. B., & Monti, D. (2015) · Springer eBooks · doi:10.1007/978-3-319-05543-5_31-1
Drugs to Modify Liver Fibrosis Progression and Regression
Vilaseca, M., & Gracia‐Sancho, J. (2022) · Springer eBooks · doi:10.1007/978-3-031-08552-9_18
The Importance of Appropriate Taurine Formulations to Target Mitochondria
Heidari, R., & Ommati, M. M. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815124484123010014
Combination of alpha-lipoic acid and mitoquinone improves myocardial function in an experimental model of myocardial infarction in aged ratsPreprint
Nemati, S., Badalzadeh, R., Oskuye, Z. Z., Mokhtari, B., Bafadam, S., & Vakili, A. (2023) · Research Square · doi:10.21203/rs.3.rs-3159392/v1
Efficacy of Mitochondrial-Based Interventions in the Management of Crohn’s Disease- A Systematic ReviewPreprint
Sauren, J., Höhfeld, D., & Keferstein, L. G. (2023) · Preprints.org · doi:10.20944/preprints202309.1722.v1
Cytotoxicity Induced by Biogenic Secondary Organic Aerosols in Neuronal CellsPreprint
Zhao, B., Xiang, W., Zhang, X., Wang, W., Du, L., Yao, L., Sun, Z., & Ge, M. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4899076
Research Progress of Kawasaki Disease and Oxidative Stress
蒋, 颖. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1482346
A Bibliometric Analysis of Oxidative Stress Research in Liver Cirrhosis: Trends, Hotspots, and Future DirectionsPreprint
Baktikulova, K., Kurmangaliyeva, S. S., Kurmangaliyev, K. B., Makashova, M., Tissin, K., & Madenbayeva, A. M. (2024) · Research Square · doi:10.21203/rs.3.rs-5648355/v1
Mitochondrial health and redox imbalance in the context of learning and memory in post-subarachnoid haemorrhage: therapeutic strategies for recovery
Rehman, A. S., Tasleem, A., Tiwari, P., Hattiwale, S. H., Jamal, A., & Parvez, S. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149881
Toxicity of Biogenic Secondary Organic Aerosol toward Nerve Cells
Zhao, B., Lei, T., Xiang, W., Zhang, X., Du, L., Yao, L., Sun, Z., Ge, M., & Wang, W. (2025) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5c00214
Role of the prolyl isomerase Pin1 in the pathogenesis of Parkinson's disease and neuroprotection by novel targeted compounds in pre-clinical animal models of the disease
Ghosh, A. (2012) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/etd-180810-1769
ROS-Mediated Cellular Signaling Pathways in Metabolic Disorders
Gunasekaran, S. K., Gobinath, M., Roychowdhury, P., Maideen, N. M. P., & Kuppusamy, G. (2026) · Springer eBooks · doi:10.1007/978-3-032-11752-6_4
Targeting mitochondrial ROS in the liver–brain axis attenuates inflammation and oxidative stress in covert hepatic encephalopathy
Bai, Y., Wang, Z., Guo, X., Yang, Z., Xie, S., Zhang, H., Nan, B., Zhang, N., Li, A., Wang, Q., et al. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.05.336
Effects of Exercise Training and MitoQ on Cardiac Atrophy and Mitochondrial Dynamics in Aged Rats
Salarmohammadi, S., Farhadfar, E., & Sarlak, Z. (2026) · Majallah-i dānishgāh-i ̒ulum-i pizishkī-i Kirmān. · doi:10.34172/jkmu.4253
Emerging roles of mitophagy in liver fibrosis: Implications for therapy
Zhao, Z., Tong, S.-N., Lin, R.-H., Feng, S.-Y., Yang, Y., & Shi, X.-J. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01908-4
Mitochondria in health and disease: cellular powerhouses, signaling centers, and drivers of dysfunction
Akinkunmi, O. A., Araba, F. F., Adaeze, C. J., Adenle, V. A., Odeyemi, A. A., Akhigbe, T. M., & Akhigbe, R. E. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1929130
Immunoinflammatory mechanisms and emerging therapies for postherpetic neuralgia
He, S., Deng, D., & Luo, W.-F. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09354-0
Mitochondrial Metabolic Reprogramming and Skin Immune Homeostasis: From Basic Mechanisms to Therapeutic Perspectives
Chen, N., Xie, X., He, S., & Liang, L. (2026) · Immune Network · doi:10.4110/in.2026.26.e35
MitoQ in sepsis-associated acute lung injury: redox pharmacology, mechanistic evidence, and translational perspectives
Yu, J., An, Y., Mi, Y., Wang, G., Wang, B., & Liu, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1975929
Hydrogen peroxide sensing and signaling in physiology and disease: implications for therapy
Mailloux, R. J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02905-z

Authors: Gane, E. J., Weilert, F., Orr, D. W., Keogh, G. F., Gibson, M., Lockhart, M. M., Frampton, C. M., Taylor, K. M., Smith, R. A. J., & Murphy, M. P.
Affiliations: Auckland City Hospital (NZ)
Waikato Hospital (NZ)
University of Otago (NZ)
MRC Mitochondrial Biology Unit (GB)
Corresponding author: Gane, Edward J.
ORCID: Gane, Edward J.
Weilert, Frank
Frampton, Christopher M.
Murphy, Michael P.
Venue: Liver International
Publisher: Wiley
Published: 2010-05-18
Volume: 30
Issue: 7
Pages: 1019-1026
ISSN: 0106-9543 (ISSN-L)
1478-3223
1478-3231
DOI: 10.1111/j.1478-3231.2010.02250.x
OpenAlex: W1623473717
Cited by: 379
References: 33
Citations by year: 2026: 18 · 2025: 29 · 2024: 15 · 2023: 26 · 2022: 29 · 2021: 27 · 2020: 33 · 2019: 24 · 2018: 28 · 2017: 21 · 2016: 24 · 2015: 21 · 2014: 23 · 2013: 18 · 2012: 23
FWCI: 12.81
Type: journal article
Language: en
Open access: closed
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1932 d)
Locations: Liver International (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Hepatitis C virus research
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: mitoquinone, chronic hepatitis C, mitochondria-targeted antioxidants, oxidative stress, mitochondrial damage, liver injury, alanine aminotransferase, aspartate aminotransferase, HCV RNA viral load, necroinflammation
MeSH terms: Administration, Oral, Adult, Alanine Transaminase, Antioxidants, Antiviral Agents, Aspartate Aminotransferases, Double-Blind Method, Female, Genotype, Humans, Interferons, Liver, Male, Middle Aged, Mitochondria, Liver, Organophosphorus Compounds, Ribavirin, RNA, Viral, Time Factors, Ubiquinone, Biomarkers, Hepacivirus, Treatment Outcome, Viral Load, Hepatitis C, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients: Mitoquinone and liver damage

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks